Tunlanut Sapankaew

Tunlanut Sapankaew

Auto-generated profile, based on publicly available information

Tunlanut Sapankaew

Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2021 in Transplant International
Verified
Journal Article
Open access
PDF file
NRNarisa Ruenroengbun
Narisa Ruenroengbun
PNPawin Numthavaj
Pawin Numthavaj
TSTunlanut Sapankaew
Tunlanut Sapankaew
KCKamolpat Chaiyakittisopon
Kamolpat Chaiyakittisopon
AIAtiporn Ingsathit
Atiporn Ingsathit
ATAmmarin Thakkinstian
Ammarin Thakkinstian
Cytomegalovirus (CMV) infection is common in kidney transplantation (KT). Antiviral-agents are used as universal prophylaxis. Our purpose aimed to compare and rank efficacy and safety. MEDLINE, Embase, SCOPUS, and CENTRAL were used from inception to September 2020 regardless language restriction. We included randomized clinical trials (RCTs) comparing the CMV infection/disease prophylaxis among antiviral-agents in adult KT recipients. Of 24 eligible RCTs, prophylactic valganciclovir (VGC) could significantly lower the overall CMV infection and disease risks than placebo with pooled risk differences (RDs) [95% confidence interval (CI)] of −0.36 (−0.54, −0.18) and −0.28 (−0.48, −0.08), respectively. Valacyclovir (VAC) and ganciclovir (GC) significantly decreased risks with the corresponding RDs of −0.25 (−0.32, −0.19) and −0.30 (−0.37, −0.22) for CMV infection and −0.26 (−0.40, −0.12) and −0.22 (−0.31, −0.12) for CMV disease. For subgroup analysis by seropositive-donor and seronegative-recipient (D+/R−), VGC and GC significantly lowered the risk of CMV infection/disease with RDs of −0.42 (−0.84, −0.01) and −0.35 (−0.60, −0.12). For pre-emptive strategies, GC lowered the incidence of CMV disease significantly with pooled RDs of −0.33 (−0.47, −0.19). VGC may be the best in prophylaxis of CMV infection/disease follow by GC. VAC might be an alternative where VGC and GC are not available.

28 March 2024 in medRxiv
Verified
Preprint
Open access
PDF file
SLSermkiat Lolak
Sermkiat Lolak
CSChaiyawat Suppasilp
Chaiyawat Suppasilp
NPNapaphat Poprom
Napaphat Poprom
TSTunlanut Sapankaew
Tunlanut Sapankaew
MYMyat Su Yin
Myat Su Yin
ATAmmarin Thakkinstian
Ammarin Thakkinstian
Background Machine learning is nowadays commonly used for disease prediction, including cardiovascular disease. There is growing evidence of the effectiveness of machine learning algorithms for stroke risk prediction models. Aims A systematic review was conducted to identify and comprehensively evaluate the available evidence. Summary of review Relevant studies were identified from the three electronic databases (i) MEDLINE via Pubmed, (ii) Scopus, and (iii) IEEE Xplore from inception to 1st December 2020. Out of 12,626 studies identified, 40 used machine learning for ischemic or hemorrhagic stroke risk prediction models. Synthesis without meta-analysis identified that a boosting algorithm (median C-statistics = 0.9 (interquartile range [IQR]: 0.88-0.92)), and neural network (median C-statistic = 0.80 (IQR: 0.77-0.92)) performed best among ML models in the low risk of bias studies. Moreover, a boosting algorithm also performed best in overall (both low and high risk of bias) studies (median C-statistic = 0.92 (IQR: 0.90-0.95)). Conclusions The systematic review found promising results of the ML algorithm model performances compare with the gold standard conventional models, such as FSRP (C-statistic 0.653) and revised FSRP (C-statistic 0.716). In term of the algorithm, boosting and neural networks are robust, but are considered as black-box models, since they are composed of non-linearity and complex algorithms. It remains questionable whether a physician would adapt these algorithms to use in a real clinical setting. Moreover, less than half of the studies (16 out of 40) were at low risk of bias in our systematic review. More researches with good methodology and study design, alongside explainable and good performance models, may become available in the future. Trial Registration Information The International Prospective Register of Systematic Reviews (PROSPERO) database (ID: CRD42021234081).